Durect's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Durect's ROI in the second quarter of 2025?
Durect Corp recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -72.53%.

Within the Healthcare sector 624 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 3068 to 4057.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Investment Change TTM	-54.89 %	-51.76 %	-52.66 %	-51.29 %	-56.87 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	3	5	9	1	5
Return On Investment (TTM)	-72.53 %	-94.77 %	-140.58 %	-232.73 %	-148.61 %
DRRX's Overall Ranking	# 4057	# 3068	# 3661	# 3495	# 4027
Seq. Investment Change TTM	-7.49 %	-12.45 %	-19.27 %	-31.01 %	-1.08 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-3	-5	-8	-17	-16

DRRX Company Profile >> Back to DRRX Roi Comparisons >> See Annual DRRX Return On Investment

Return On Investment DRRX's Ranking
Within:	No.
Industry	# 282
Sector	# 625
Overall	# 4057

Return On Investment Statistics
High	Average	Low
45.07 %	-71.65 %	-243.4 %
(Dec 31 2012)		(Sep 30 2023)

Financial Statements
Durect's II. Quarter Investments	$ 3 Millions	DRRX's Balance sheet
Durect's II. Quarter Income	$ -2 Millions	Quarterly DRRX's Income Statement
DRRX's Income by Division		See DRRX's Income by Division

DRRX Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	9	15	25	82	65
Y / Y Investment Growth	-38.23 %	-40.83 %	-69.51 %	26.17 %	31.85 %
Net Income in Millions	-8	-28	-35	-36	-1
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-91.16 %	-186.86 %	-141.42 %	-44.26 %	-0.9 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
DRRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for DRRX's Competitors
Subscribers only: Roi for Durect's Suppliers
Subscribers only: Return On Investment for DRRX's Customers

Other Ratios
DRRX's Roa	DRRX's Inventory Turnover Ratio	DRRX's Growth Rates	DRRX's Dividend Statistics
	DRRX's Profitability Ratios	DRRX's Asset Turnover Ratio	DRRX's Dividend Growth
DRRX's Roe	DRRX's Valuation Ratios	DRRX's Financial Strength Ratios	DRRX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector

ROI

Date modified: 2026-08-29T17:24:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.